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Abstract
Background: Presently the level of blood pressure (BP) control is extremely unsatisfactory in hypertensive patients 
throughout the world. The aim of our study was to find the optimal drug therapy for patients with hard-to-treat 
essential hypertension (EH) associated with type 2 diabetes mellitus (T2DM) and obesity, namely the comparison 
of strategies of fixed and non-fixed combination.
Material and methods: Eighty-seven patients with EH, T2DM and obesity were enrolled into the study. Two groups 
were formed: the 1st group — 41 patients received antihypertensive therapy in the form of unfixed combination of 
drugs (“multi-pill”) perindopril, indapamide and amlodipine; the 2nd — 46 patients, who received the same drugs, 
but in a fixed-dose combination (“single pill”).
Results: A favorable treatment result was found for fixed-dose combination of antihypertensive  drugs, with signifi-
cant reduction in the frequency of visits to the doctor: relative risk (RR) — 1.27 (95% CI: 1.01‒1.61), p = 0.045, 
and odds ratio (OR) — 3.10 (95% CI: 1.05‒9.13), p = 0.04. That indicates that patients on fixed-dose combination 
were less likely to visit a doctor with complaints. Patients on single-pill therapy were less likely to get to progression 
(worsening) group in contrast to multi-pill non-fixed combination: RR — 1.37 (95% CI: 1.02‒1.84), p = 0.03; 
OR — 2.91 (95% CI: 1.12‒7.59), p = 0.03.
Conclusion: The single-pill triple combination has significant advantage compared to multi-pill regimen in hard-to-
treat hypertensive patients with comorbid T2DM and obesity. Fixed-dose triple combination leads to significantly 
faster achievement of blood pressure control.
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Introduction
A high level of blood pressure is among the main rea-
sons of early disabling cardiovascular complications 
(CVC) such as myocardial infarction and stroke. 
Poor control of blood pressure (BP) remains among 
the major problems in contemporary cardiology. At 
the moment BP control in hypertensive patients is 
extremely unsatisfactory [1]. Unsatisfactory national 
cardiovascular regulations, low patients’ adherence 
to prescribed treatment schemes, and the so-called 
specialists’ inertia are factors responsible for the 
mentioned problem. Also it is worth to point out 
the next important factor promoting inappropri-
ate BP control is the confined use of antihyperten-
sive drug combinations. Despite the fact that there 
is enough evidence that combination treatment 
leads to more effective BP control in comparison to 
monotherapy [2].
Nowadays, there are drugs that can effectively af-
fect blood pressure and therefore reduce the risk of 
stroke, kidney and cardiovascular disease in the arse-
nal of the clinician, but uncontrolled blood pressure 
and low adherence to antihypertensive drugs remains 
one of the main clinical problems [3]. 
The treatment of essential hypertension (EH) pre-
dominantly includes well-known medications from 
five main classes of drugs: angiotensin-converting 
enzyme inhibitors (ACEIs), angiotensin II receptor 
blockers (ARBs), diuretics, calcium channel blockers 
(CCB), and b-blockers. There is bounded variation 
by race, age, gender in choosing of antihypertensive 
agents. Only 58% of treated patients had SBP < 140, 
24% had unsatisfactory controlled BP with SBP ≥ 
150, evidencing the effectiveness of treatment needs 
to be improved [4].
Long-term prospective studies have shown that 
patients with hypertension did not receive effective 
monotherapy and needed an average of two or three 
drugs for adequate control [5].
Despite mentioned data, BP control is poor in 
majority of countries. Contemporary investigations 
revealed, regardless the location (country) and ir-
respective to the high- or low-income economies, 
just about 40% of patients with hypertension are 
treated; of these approximately about 35% have well 
controlled blood pressure with BP values less 140/90 
mm Hg [6].
All mentioned above justifies the search for ad-
equate methods of treatment of patients with EH, 
especially in the presence of polymorbidity: type 
2 diabetes mellitus (T2DM) with obesity. Special 
difficulties are present when solving the problem of 
antihypertensive therapy in high-risk patients with 
additional comorbidities — T2DM with obesity. 
Thus, if in the general population of patients with 
EH effective control is achieved in approximately 
15–20% of such patients, then when combined with 
T2DM and obesity, this percentage becomes even 
more unfavorable, even dramatic values, which in 
turn leads to an increase in adverse events, CVC and 
reduced life expectancy and earlier disability [6, 7].
The question arises, what strategy of drug treat-
ment in such patients is the most optimal? The 
problem is exacerbated by the fact that the clinician 
often decides to prescribe antihypertensive therapy 
to a patient who has additional pathology (T2DM, 
obesity) and who has suffered from EH for many 
years and the antihypertensive treatment used so far 
has been ineffective. Thus, it is not a question of the 
so-called first line therapy, but of solving the question 
of finding an effective strategy in such (polymorbid) 
patients with EH who have experienced treatment 
failure and have poorly controlled blood pressure 
despite prescribed therapy.
The aim of the study was to find the optimal drug 
therapy for patients with long-lasting essential hy-
pertension associated with type 2 diabetes mellitus 
and obesity, namely the comparison of strategies of 
fixed combination of antihypertensive drugs with the 
strategy of non-fixed combination.
Material and methods
The 87 patients with EH, type 2 diabetes and obesity 
were enrolled into the study. Examined subjects were 
patients admitted to Cardiology Departments of O.I. 
Meshchaninov City Clinical Hospital of Ambulance 
and Emergency Care and Kharkiv Regional Hospital 
who had elevated arterial blood pressure and were 
over 37 years of age. Two groups of medicament 
strategy were formed: the 1st group — 41 patients 
with EH, T2DM and obesity, who received antihy-
pertensive therapy in the form of unfixed combina-
tion of drugs or “multi-pill” (NFC) — perindopril at 
a daily dose of 4 mg, indapamide (1.25 mg per day) 
and amlodipine (5 mg); the 2nd group — 46 patients 
with EH, T2DM and obesity, who received the same 
combination of drugs, but in the single pill — a fixed 
combination. The drug was used in a dose of 1 tablet 
per day, regardless of food intake, preferably in the 
morning. 
In the study, the combination of EH with T2DM 
and obesity required the application of the antidia-
betic and hypolipidemic therapy in addition to the 
antihypertensive treatment. Metformin or, if neces-
sary, a combination of metformin with gliclazide, and 
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atorvastatin, or rosuvastatin was used. The patients 
with the stable coronary artery disease were prescribed 
acetylsalicylic acid. Thus, the treatment strategy was 
to act on the normalization of blood pressure and 
blood glucose, lowering total cholesterol and triglyc-
erides, and included diet aimed at weight loss.
Two treatment regimens were evaluated by com-
paring their positive and negative effects. After that 
frequencies of good and negative results in the groups 
were calculated. The scheme with an unfixed com-
bination of antihypertensive drugs was considered 
as a control to the scheme with a fixed combina-
tion. When calculating the relative risk (RR), visiting 
a physician due to any kind of complaints associated 
with hypertension-mediated organ damage (head-
ache, chest pain, shortness of breath, fatigue, the 
appearance of flicker before the eyes, difficulty falling 
asleep, mood swings, etc.) was referred as negative 
results.
The both groups were matched by all investigated 
parameters — age, gender, additional risk factors, 
physical state etc.
All patients signed informed consent and Insti-
tutional Ethical Committee of the participating 
center approved the protocol of the study (number 
2018/05/02), that was performed according to the 
requirements and norms of the ICH GCP (2002), 
and following the Declaration of Helsinki, as well 
as standard provisions on ethics of the Ministry of 
Health of Ukraine No. 66 13.02.2006.
The examination of hypertensive patients with 
T2DM and obesity was carried out 3 and 6 months 
after treatment. The target level of SBP was consid-
ered as 130/80 mm Hg. 
Statistical analysis. The data is presented as mean 
± standard deviation (M ± SD) or percentage (%). To 
determine the association between treatment strategy 
and outcome (result of the therapy) the relative risk 
and the odds ratio (OR) with 95% confidence inter-
val (CI) were calculated. OR is most often used in 
case-control studies, but it can also be used in a one-
step intergroup study and in a cohort study (with 
some assumptions) [8]. The target levels’ frequencies 
and the medicament treatment regimen were com-
pared between two groups by the c2 test. Statistical 
significance was considered as p value < 0.05. Med 
Cal (v. 19.3) program was used to calculate and ana-
lyze obtained data. 
Results
The baseline characteristics of enrolled patients are 
presented in Table 1. 
The baseline characteristics of enrolled patients 
show that patients from both treatment regimens 
Table 1. Baseline characteristics of patients in the study groups (M ± SD)
Parameters All patients Fixed combination (single-pill)(n = 46)
Non-fixed combination (multi-pill)
(n = 41)








Systolic blood pressure [mm Hg] 161.32 ± 7.65* 161.56 ± 6.98* 160.89 ± 7.49*
Diastolic blood pressure [mm Hg] 96.78 ± 4.92* 96.89 ± 4.87* 95.91 ± 5.01*
HbA1c (%) 7.1 ±1.41* 7.0 ±1.42* 7.1 ± 1.33*
EH duration [yrs] 11.12 ± 4.34* 10.91 ± 4.02* 11.65 ± 3.97*
Obesity duration [yrs] 13.32 ± 4.43* 14.03 ± 3.53* 13.11 ± 4.39*
T2DM duration [yrs] 7.83 ± 3.32* 8.05 ± 2.81* 7.66 ± 2.90*
BMI [kg/m2] 35.43 ± 3.46* 36.11 ± 3.52* 35.03 ± 3.43*
Heart failure [NYHA FC]
0: 5 (5.8 %)*
I: 19 (21.8%)*
II: 63 (72.4%)*






Smokers (%) 28 (32.2 %)* 15 (32.6 %)* 13 (31.7%)*
Dyslipidemia (%) 60 (69.0%)* 31 (67.4 %)* 29 (70.7%)*
LV hypertrophy (%) 87 (100.0%)* 46 (100.0%)* 41 (100.0%)*
Carotid intima-media thickness > 0.9 mm (%) 55 (63.2%)* 29 (63.0%)* 26 (63.5%)*
Microalbuminuria (20 to 200 mg/L) (%) 71 (81.6 %)* 38 (82.6%)* 80.5%)*
*the p level significance p > 0.1 (differences between groups); EH — essential hypertension; T2DM — diabetes mellitus type 2; BMI — body mass index; LV — left ventricle; NYHA FC 
— New York Heart Association Functional Classification 
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were consequently matched by all investigated pa-
rameters.
A favorable treatment result was found in the 
polymorbid group receiving fixed antihypertension 
combination that was proved by significant reduc-
tion in the frequency of visits to the doctor, with cal-
culated RR — 1.27 (95% CI: 1.01‒1.61), p = 0.045 
and OR — 3.10 (95% CI: 1.05‒9.13), p =  0.04 
(Tab. 2).
Thus, this calculation indicates in favor of 
a scheme with a fixed combination compared to 
a non-fixed one. Thus, values of relative risk of 1.27 
(95% CI: 1.01–1.61) indicate that patients who re-
ceived a fixed combination of drugs were less likely 
to visit a doctor with complaints on hypertension-
mediated target organ damage (HMTOD).
The influence of the two treatment options on 
the dynamics of the clinical condition assessed by 
the 6-min walking test was also analyzed. Improving 
the performance of the 6-minute walking test were 
recorded in 96% of patients taking a fixed triple 
combination, and in the group taking three separate 
drugs; the increase in test scores was observed in 85% 
of patients.
Comparison of 6-min walking test results did 
not showed significant advantage of the triple regi-
men in one tablet over taking three separate anti-
hypertensive drugs. It was found, that calculations 
of RR — 0.99 (95% CI: 0.83‒1.18), p = 0.94 and 
OR — 0.96 (95% CI: 0.29‒3.11), p = 0.94 indi-
cate that the probability of clinical improvement 
did not reach statistical significance between groups 
(Tab. 2).
Progression (worsening) of patients’ condition 
with EH, T2DM mellitus and obesity was assessed 
by the dynamics of structural and functional param-
eters of the target organs (heart, kidneys and blood 
vessels). It was revealed (Tab. 2) that patients taking 
fixed combination were less likely to get to progres-
sion group (group with worsening of condition) than 
those on non-fixed combination: RR — 1.37 (95% 
CI: 1.02‒1.84), p = 0.03; OR — 2.91 (95% CI: 
1.12‒7.59), p = 0.03.
This result of calculations of HR and OR indicates 
that the use of triple-drug single-pill combination 
(SPC) is much more effective in preventing deterio-
ration of the target organs in hypertensive patients 
with polymorbidity. We can assume that this is due 
to more careful control and faster achievement of 
target blood pressure levels.
After 3-month treatment (Fig. 1) with a three-
component antihypertensive regimen the target 
levels of systolic blood pressure were achieved in 
33 hypertensive patients on unfixed combination, 
and number of patients on fixed combination who 
reached target levels was 44 (p < 0.001). An impor-
tant result is the data of blood pressure control after 
6 months, which demonstrate the effectiveness of 
both selected strategies in achieving the target levels 
of blood pressure — 97.83% and 92.68% of patients 
receiving fixed and non-fixed combinations, respec-
tively (Fig. 1). Thus, there is a significant advantage 
of antihypertensive therapy with the use of a fixed 
combination, which led to a much faster achieve-
ment (p < 0.05) of blood pressure — 130/80 mm 
Hg.
Thus, taking a fixed combination (an ACE in-
hibitor — perindopril, a diuretic — indapamide 
and a calcium channel blocker — amlodipine) 
along with the antihyperglycemic therapy (metfor-
min or a combination of metformin and gliclazide) 
and recommendations for lifestyle modification 
was significantly better compared with non-fixed 
combinations of antihypertensive drugs (Figure 1): 
after 3 months it lead to significantly higher per-
centage of patients achieving target blood pressure 
— 95.65% (44 patients) against 80.49% (33 patients) 
(c2 = 4.84; p = 0.03) and after 6 months 97.83% 
(45 patients) against 92.68% (38 patients) (c2 = 1.30; 
p = 0.26). The fixed combination definitely reduces 
the risk of progression (clinical worsening) of the hy-
pertensive patient with T2DM mellitus and obesity 
Table 2. Influence of single-pill (fixed combination) and multi-pill (unfixed combination) strategies on the frequency of visits to the doctor, 
6-minute walking test, and clinical state in patients with essential hypertension, type 2 diabetes mellitus (T2DM) and obesity
RR (95% CI) OR (95% CI)
Visiting a physician 1.27 (1.01–1.61) 3.10 (1.05–9.13)
p value p = 0.045 p = 0.04
6-minute walking test 0.99 (0.83–1.18) 0.96 (0.29–3.11)
p value p = 0.94 p = 0.94
Clinical worsening (progressing) 1.37 (1.02–1.84) 2.91 (1.12–7.59)
p value p = 0.03 p = 0.03
RR — relative risk; CI — confidence interval; OR — odds rate
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history of ineffective BP lowering treatment was in-
vestigated. The majority of publications are devoted 
to the problem of the first-line therapy [10–12]; in 
contrast, we tried to find out better strategies in those 
patients who were unsuccessful with recommended 
first-line treatments. Also we tried to evaluate (to 
measure) exact preferences of single-pill triple regi-
men over multi-pill format.
Nowadays the issue of antihypertensive therapy 
in diabetics remains the cornerstone, and a lot of 
research has been devoted to this aspect, and often 
their results are contradictory. In general, it can be 
concluded from meta-analyses that antihypertensive 
treatment significantly reduces cardiovascular out-
comes in diabetic and non-diabetic patients. Dia-
betic patients have uncertain benefits in intensive 
SBP lowering to less 120 mm Hg, while such inten-
sive BP control is associated with evident benefits in 
those without diabetes mellitus [13]. At the same 
time, reducing ESRD risk has been evidenced only in 
diabetics (when SBP < 130 mm Hg). Meta-analyses 
showed that all BP-lowering drugs are effective in di-
abetic patients, with renin–angiotensin system block-
ers preferably included in the treatment schemes of 
patients with diabetes mellitus [9, 14, 15].
On the contrary, Bangalore’s study state that in 
diabetics RAS blockers have no superior effects com-
pared to other antihypertensive medicaments, such 
as diuretics, calcium channel blockers, or b-blockers, 
in diminishing the risk of undesirable cardiovascular 
and renal events. These resulted in recommendations 
of the guidelines of the European and American 
during 6 months of treatment: 80.43% vs. 58.54% 
(c2 = 4.90; p = 0.03).
Discussion
The mentioned triple combination was chosen for 
the study because of the best evidence based data 
among the drugs used in hypertension. Perindopril is 
one of the best representatives of the ACE inhibitor 
class. It showed high hypotensive efficacy, reduction 
of overall mortality in patients with EH, as well as 
a probable reduction in the overall risk of cardiovas-
cular complications in patients with stable coronary 
heart disease and preserved left ventricular function 
(ASCOT-BPLA, ADVANCE, HYVET, EUROPA, 
PERSPECTIVE, PERTINENT). Indapamide is also 
the optimal drug in its class. It is a metabolically 
neutral diuretic that has a significant antihyperten-
sive effect and is proven to reduce the incidence of 
cardiovascular complications in patients with hyper-
tension (HYVET, ADVANCE, PROGRESS, PATS). 
Amlodipine, in turn, is one of the most powerful 
CCB. It showed a marked reduction in cardiovas-
cular complications (both cardiac and cerebral) in 
patients with EH, especially in combination with 
ACE inhibitors (ASCOT and ACCOMPLISH). In 
addition, both perindopril and amlodipine have pro-
nounced renoprotective properties [6, 9].
It is desirable to underline that the main feature of 
our study was that medicament treatment in hyper-
tensive patients with high CV risk and with previous 
Figure 1. Results of studied treatment strategies: after 3 months and after 6 months. Results are presented as proportions of patients (%) 
achieved target blood pressure (BP) 
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societies on management of hypertension to use any 
antihypertensive drugs in diabetic people but with 
normal renal function [16].
Grossman et al. assessed evidence supporting 
different BP targets in diabetics and reviewed the 
various guidelines on this topic. Moreover, they dis-
cussed the different variants available for the BP low-
ering in diabetics. The authors are more inclined to 
choose RAAS blockers as the first-line agents among 
anti-hypertensive drugs. In this study, as in our in-
vestigation, calcium channel blocker and/or thiazide 
were preferable as second line medications in case it 
was necessary to use more than one drug for the BP 
control in patients with diabetes. In Grossman et 
al.’s study it was stated that new anti-diabetic agents 
could be more effective in antihypertensive treatment 
and might change the physician’s choice in the treat-
ment of T2DM. On the contrast, we used traditional 
well-recommended drug as metformin in our study. 
In addition, it is essential to manage all other risk 
factors in hypertensive patients with T2DM when 
decreasing BP. Grossman et al. concluded that indi-
vidual flexible treatment model, reflecting the gen-
eral modern trends in medicine, proved the need for 
individually tailored medicine, adapted specifically 
for the particular anthropological and morphologi-
cal characteristics of every person [17]. Such result 
is also supported by our team, but at the same time, 
we understand that it is necessary to find optimal 
treatment recommendation for specific cohort of hy-
pertensive patients — with prolonged history of EH 
with comorbid T2DM and obesity.
The systemic review by Brunström Mattias et al. 
indicates that the available data point out the need 
for a decrease in SBP to more than 140 mm Hg in 
people with T2DM. At the same time, these authors 
did not find differences in the effectiveness between 
the main antihypertensive drugs: angiotensin-con-
verting enzyme inhibitors, ARBs, b-blockers, cal-
cium channel blockers and diuretics in the preven-
tion of general or cardiovascular mortality, as well 
as coronary artery disease and ESRD. Furthermore, 
minor additional effects have been found for stroke 
and heart failure. It is important to note that in this 
study there were limitations on the inclusion criteria 
and patients with type 1 diabetes and very elderly 
patients with T2DM were excluded from the study, 
which differs from our study [18].
The initial treatment should be started with two 
drugs or a single-pill combination of drugs proven to 
reduce cardiovascular events in patients with diabe-
tes. Recommendation of class A insist on poly-drug 
strategy to control blood pressure targets (but not 
usage of ACEI with ARB combination), herewith 
there is no indication on previous treatment history. 
The initial treatment for diabetic patients depends 
on the severity of hypertension, but in our study 
it is defined by previous treatment effectiveness. In 
diabetic patients with BP over 160/100 mm Hg, 
initial pharmacological treatment is recommended 
with two antihypertensive medications, whereas the 
presence of such additional risk factor as obesity is 
not discussed deeply [19].
Also, we want to point out the need for wider 
implementation of single-pill combination in the 
routine practice, according to hypertension treat-
ment algorithms included in the 2018 ESC guide-
lines [6]. Combination treatment leads to a faster 
achievement of BP control in comparison to mono-
therapy. That is essential in many cases and can 
be crucial. Herewith, the implementation of the 
fixed combination approach into everyday clinical 
practice should be supported by initiatives aimed at 
resolving physicians’ and patients’ barriers such as 
low experience of use, miscellaneous perception of 
SPC, lack of confidence in the independence of rec-
ommendations, patient-physician communication. 
The concept of first-line antihypertensive therapy 
needs to be promoted with help of national CME 
programs and lists of available SPCs, print media 
and digital materials [20].
Fixed-dose combinations as initial therapy are 
often needed to achieve fast blood pressure control 
[21]. On the other hand, European guidelines do 
not recommend initial triple therapy under any 
circumstance, but here we firmly underline that 
only in initial (starting) phase, but not in general. 
Moreover, we also emphasize in our work more 
firm and definite usage of fixed triple combination 
in high-risk hypertensive patients with diabetes 
and obesity who had prolonged ineffective treat-
ment history. 
There are limited investigations of antihyperten-
sive treatment in polymordid patients who have a lot 
of additional risk factors, which forced us to do 
presented study.
The distinguishing feature of our work was that 
the proven benefits of prescribing a fixed triple com-
bination were calculated. It was also emphasized that 
the effect of a triple fixed combination was noted 
only in this high-risk group (that is, with multi-
morbidity) with a documented history of long-term 
hypertension and ineffective blood pressure control. 
In other cases — for example, in patients naïve to an-
tihypertensive therapy, it is most likely to start with 
a fixed two-component combination.
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It is fundamentally important to note that we 
included patients with both type 2 diabetes and obe-
sity.
It was an obligatory inclusion criterion to have 
previous experience of ineffective drug therapy, 
which, from our point of view, represents a huge pro-
portion of hypertensive patients. In addition, these 
patients are most often people with modest financial 
resources.
And, most importantly, specific benefits from 
a fixed combination were calculated — significant-
ly fewer visits to the doctor, decreased numbers of 
complaints and concerns raised, improved prognosis 
— reduction of target organ damage and improved 
quality of blood pressure control.
The presented study had some limitations — 
a small sample and comparison of frequencies in 
this case can be regarded as the limit of the study. It 
is also worth noting the relatively short-term of the 
study. It can be assumed that a longer observation 
would make it possible to find additional advantages 
of a fixed triple combination or, on the contrary, to 
reduce them.
Further research is needed in this cohort of pa-
tients, who are at increased risk — with a large 
sample size and prolonged exposure.
Conclusion
The non-first line antihypertensive regimen with 
single-pill triple combination has significant advan-
tage compared to multi-pill (non-fixed) regimen in 
hard-to-treat hypertensive patients with comorbid 
2 type diabetes mellitus and obesity. Such one-pill 
combination leads to significantly faster achievement 
of blood pressure control and decreases the chances 
of worsening of patients’ state or/and diminishes 
chances to disease development. 
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